MedTrace Logo

Clinicaly Manifested Reinfections with Borrelia Burgdorferi Sensu Lato

NCT06835075 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2025-02-21

No results posted yet for this study

Summary

Data on reinfections with B. burgdorferi sensu lato in humans are scarce; they are limited to case reports and a few small groups of patients, mostly from the USA and less frequently from Europe. In these reports, the clinical manifestation of reinfection was usually erythema migrans and was most often documented after successful treatment of a previous infection (almost always erythema migrans). The clinical manifestations of Lyme disease in reinfection appear to be similar to those of primary infection, but there are no studies on possible differences in serological or immunological responses.

The current study has 3 primary objectives:

* To determine the frequency of clinically detectable reinfections and to identify the circumstances under which they occur;
* To determine possible differences between primary and reinfection in clinical presentation, disease course and outcome, and specific serum antibody response;
* To determine the aetiology of clinically detectable reinfections by comparing Borrelia isolates recovered from the skin of the same patient at primary and reinfection.

Conditions

  • Lyme Borreliosis

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-31
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06835075 on ClinicalTrials.gov